or Try an Advanced Search...

    Overactive Bladder Stocks List

    Symbol Grade Name % Change
    MDT B Medtronic Inc. 0.92
    URGN F UroGen Pharma Ltd. -0.49
    View As Page of Charts
    Related Industries: Biotechnology Medical Devices
    Related Stock Lists: Medicine Ablation Ablation Products Advanced Energy Antineoplastic Drugs Atrial Fibrillation Biologic Product Biologic Products Biopharmaceutical Bladder Cancer Bone Botulinum Toxin Bypass Cancer Carcinoma Cardiac Electrophysiology Catheter Chemotherapy Chronic Pain Cordis

    Related ETFs - A few ETFs which own one or more of the above listed Overactive Bladder stocks.

    Symbol Grade Name Weight
    PCIG F Polen Capital International Growth ETF 5.31
    ABEQ C Absolute Core Strategy ETF 4.6
    IHI A iShares U.S. Medical Devices ETF 4.5
    CAMX A The Advisors? Inner Circle Fund Cambiar Aggressive Value ETF 4.38
    DIVP C Cullen Enhanced Equity Income ETF 4.07
    View all Overactive Bladder ETFs...
    Compare ETFs
    Compare ABEQ to DIVP Compare IHI to DIVP Compare PCIG to CAMX

        Overactive Bladder Stocks Recent News

        Date Stock Title
        Nov 1 MDT Medtronic (MDT) Outperforms Broader Market: What You Need to Know
        Nov 1 MDT CMS grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral™ renal denervation catheter
        Oct 31 MDT Edwards, Medtronic and Inari share trial data at TCT conference
        Oct 31 MDT Boston Scientific’s Acurate Neo2 inferior to Edwards, Medtronic TAVR valves in study
        Oct 31 MDT Medtronic: Undervalued But Trapped In Slow Growth (Rating Downgrade)
        Oct 30 URGN UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
        Oct 29 MDT Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock
        Oct 29 MDT Medtronic’s Symplicity Spyral RDN system shows sustained BP reduction
        Oct 28 MDT Medtronic (MDT) Ascends But Remains Behind Market: Some Facts to Note
        Oct 28 MDT SPYRAL HTN-ON MED study shows significant, consistent, long-term blood pressure lowering effect at two years
        Oct 28 URGN ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
        Related Industries: Biotechnology Medical Devices
        Related Stock Lists: Medicine Ablation Ablation Products Advanced Energy Antineoplastic Drugs Atrial Fibrillation Biologic Product Biologic Products Biopharmaceutical Bladder Cancer Bone Botulinum Toxin Bypass Cancer Carcinoma Cardiac Electrophysiology Catheter Chemotherapy Chronic Pain Cordis
        Overactive Bladder

        Overactive bladder (OAB) is a condition in which the bladder muscles contract uncontrollably, causing a sudden and frequent urge to urinate. People with OAB may also experience urinary incontinence, or the inability to control the release of urine. OAB is a common condition that affects millions of people worldwide. Treatment options include lifestyle changes, medications, and in some cases, surgery.

        Browse All Tags